Cor Vasa 2008, 50(4):156-162 | DOI: 10.33678/cor.2008.054
The quality of secondary prevention of coronary heart disease in Czech patients in the EURO-ASPIRE III survey.
- 1 Centrum preventivní kardiologie, II. interní klinika, Fakultní nemocnice Plzeň a Lékařská fakulta Univerzity Karlovy, Plzeň
- 2 Pracoviště preventivní kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika
Introduction:
The main objectives of prevention are to reduce morbidity and mortality, and to improve quality of life.
Aim:
To determine, in patients with coronary heart disease, whether the treatment goals, as defined by current guidelines on secondary prevention, are implemented in clinical practice.
Methods:
A total of 600 consecutive patients, men and women aged ≤ 80 years, were identified retrospectively with the following diagnoses: coronary artery bypass grafting, percutaneous transluminal coronary angioplasty or acute coronary syndrome. Data collection was based on a review of medical records and interview at least six months after hospital admission.
Results:
In total, 493 responders were interviewed. Among them, 21% were smokers, 37.3% were obese, 54% had raised blood pressure (≥ 140/90 mmHg or 135/80 mmHg in those with diabetes), 56.8% had elevated LDL-cholesterol (≥ 2.5 mmol/l) and 42% had overt diabetes (glucose > 7 mmol/l or antidiabetic treatment). At interview, 88% of patients were treated with beta-blockers, 60.2% with ACE inhibitors, 81.9% with statins and 92.7% with aspirin or anticoagulants. Only a minority of patients followed the non-pharmacologic recommendations.
Conclusion:
In spite of marked improvement in pharmacotherapy, there is a considerable potential to raise the standard of preventive cardiology through optimal control of risk factors to defined targets and, moreover, through improvement in non-pharmacologic interventions of life-style factors.
Keywords: Secondary prevention; Guidelines; EUROASPIRE III
Published: April 1, 2008 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Pyörälä K, de Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendation of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994,15:1300-31.
Go to original source...
Go to PubMed...
- Šimon J, Rosolová H, Šamánek M. Doporučení pro prevenci ischemické choroby srdeční a dalších komplikací aterosklerozy v klinické praxi a v populaci. Cor Vasa 1998;40:K99-K106.
- EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997;18:1569-82.
Go to original source...
Go to PubMed...
- Wood D, De Backer G, Faergeman D, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.
Go to original source...
- EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Eur Heart J 2001;22:554-72.
Go to original source...
- Mayer O Jr, Šimon J, Rosolová H, et al. on behalf Euroaspire I a II study groups. The pursuit of secondary prevention targets in czech coronary patients. A comparison of Euroaspire I and II surveys. Centr Eur J Pub Health 2002;3:107-11.
- De Backer G, Ambrossioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention on clinical practice. Third joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.
Go to original source...
Go to PubMed...
- Hagströmer M, Oja P, Sjöström M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr 2006; 9:755-62.
Go to original source...
Go to PubMed...
- McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
Go to original source...
- Stafford L, Berk M, Jackson HJ. Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease. Gen Hosp Psychiatry 2007;29: 417-24.
Go to original source...
Go to PubMed...
- Silagy C, Stead LF. Physician advice for smoking cessation. Cochrane Database Syst Rev 2001;2:CD000165.
Go to original source...
- Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2001;3:CD000146.
Go to original source...
- Wilson K, Dimoulas P, Mills EJ, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006;6:300.
Go to original source...
Go to PubMed...
- Škodová Z, Cífková R, Adámková V, et al. Vývoj kuřáckých zvyklostí obyvatelstva České republiky v období 1985-1997/98. Čas Lék čes 2000;139:145-7.
- Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
Go to original source...
Go to PubMed...
- Filipovský J, Šimon J, Chrástek J, et al. Changes of blood pressure and lipid pattern during a physical training course in hypertensive subjects. Cardiology 1991;78:31-8.
Go to original source...
Go to PubMed...
- Berkman LF, Blumenthal J, Burg M, et al. Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:3106-16.
Go to original source...
Go to PubMed...
- Glassman AH, O'Connor CM, Califf RM, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9.
Go to original source...
Go to PubMed...